Health Care [ 9/12 ] | Biotechnology [ 37/73 ]
NASDAQ | Common Stock
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -0.88 Decreased by -72.55% | -0.53 Decreased by -66.04% |
| May 7, 25 | -0.82 Decreased by -51.85% | -0.71 Decreased by -15.49% |
| Mar 19, 25 | -0.81 Decreased by -14.08% | -0.76 Decreased by -6.58% |
| Nov 7, 24 | -0.72 Increased by +80.95% | -0.59 Decreased by -22.03% |
| Aug 8, 24 | -0.51 Increased by +41.13% | -0.55 Increased by +7.27% |
| May 9, 24 | -0.54 Decreased by -14.89% | -0.44 Decreased by -22.73% |
| Mar 21, 24 | -0.71 Decreased by -136.67% | -1.01 Increased by +29.70% |
| Nov 9, 23 | -3.78 Decreased by -1.30 K% | -0.56 Decreased by -575.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 193.00 K Decreased by -89.64% | -31.63 M Decreased by -79.64% | Decreased by -16.39 K% Decreased by -1.63 K% |
| Mar 31, 25 | 1.16 M Increased by +33.07% | -29.51 M Decreased by -114.66% | Decreased by -2.54 K% Decreased by -61.32% |
| Dec 31, 24 | 1.33 M Increased by +190.15% | -28.44 M Decreased by -169.24% | Decreased by -2.14 K% Increased by +7.21% |
| Sep 30, 24 | 2.17 M Increased by +135.06% | -25.17 M Decreased by -70.52% | Decreased by -1.16 K% Increased by +27.46% |
| Jun 30, 24 | 1.86 M Increased by +92.26% | -17.61 M Decreased by -436.14% | Decreased by -945.09% Decreased by -178.86% |
| Mar 31, 24 | 874.00 K Increased by +83.61% | -13.75 M Increased by +52.87% | Decreased by -1.57 K% Increased by +74.33% |
| Dec 31, 23 | 457.00 K Decreased by -61.11% | -10.56 M Decreased by -4.42% | Decreased by -2.31 K% Decreased by -168.47% |
| Sep 30, 23 | 924.00 K Decreased by -21.23% | -14.76 M Decreased by -89.66% | Decreased by -1.60 K% Decreased by -140.77% |